VALNEVA (EPA:VLA) | Finanzwire

Basculer en Français

10047	Companies
204823	Keywords
135077	Articles
108596	Press releases

Home
Companies
VALNEVA

PRESS RELEASE

published on 08/20/2024 at 16:01, 1 year 6 months ago

Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH updates research on Valneva SE (ISIN: FR0004056851) with a BUY recommendation and EUR 8.60 price target. H1 product sales slightly below consensus but gross margin improving. Valneva maintains full-year guidance

First Berlin Equity Research Buy Recommendation Valneva SE EUR 8.60 Price Target H1 Product Sales
BRIEF

published on 08/13/2024 at 07:05, 1 year 7 months ago

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

Financial Results Cash Position Revenue Guidance Valneva Vaccine Development
PRESS RELEASE

published on 08/13/2024 at 07:00, 1 year 7 months ago

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates
Valneva reports first-half 2024 financial results as total revenues reach €70.8 million with net profit of €34.0 million. Company confirms full-year guidance and updates strategic pipeline expansion

Revenues Financial Results Net Profit Valneva Strategic Pipeline
BRIEF

published on 08/06/2024 at 08:35, 1 year 7 months ago

Valneva Announces Share and Voting Right Changes as of July 31, 2024

Euronext Paris Voting Rights Shares Biopharmaceutical Valneva
PRESS RELEASE

published on 08/06/2024 at 08:30, 1 year 7 months ago

VALNEVA - Declaration of shares and voting rights: July 31, 2024
VALNEVA declared changes in shares and voting rights including sale, transfer, and granting of double voting rights on various dates

Voting Rights Shares Sale Transfer Valneva
BRIEF

published on 07/17/2024 at 22:05, 1 year 8 months ago

VALOR Phase 3 Trial: Valneva and Pfizer Finalize Primary Lyme Disease Vaccination

Clinical Test Valneva Pfizer VLA15 Lyme
PRESS RELEASE

published on 07/17/2024 at 22:00, 1 year 8 months ago

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion
Phase 3 VALOR Lyme Disease Trial: Pfizer and Valneva announce completion of primary vaccination series with VLA15, progressing towards a Lyme disease vaccine

Valneva Lyme Disease Vaccine Pfizer VLA15 VALOR
BRIEF

published on 06/05/2024 at 07:05, 1 year 9 months ago

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

Executive Changes Corporate Update Valneva Shareholder Meeting
PRESS RELEASE

published on 06/05/2024 at 07:00, 1 year 9 months ago

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
Valneva announces availability of documentation for its Combined Shareholder Meeting on June 26, 2024, along with corporate update including change in General Counsel & Corporate Secretary. Kendra Wergin appointed as successor

Corporate Update Valneva General Counsel Shareholder Meeting Kendra Wergin
BRIEF

published on 05/21/2024 at 07:05, 1 year 9 months ago

Valneva appoints Dr Hanneke Schuitemaker as Scientific Director

Nomination R&D Valneva Vaccines Dr Hanneke Schuitemaker

Accesswire

Published on 03/17/2026 at 23:10, 26 minutes ago

Redwood AI CEO Louis Dron Featured on Conversations That Matter to Discuss AI Chemistry Platform and Broader Applications
Published on 03/17/2026 at 22:30, 1 hour 6 minutes ago

Galway Metals Appoints Red Cloud Financial Services to Provide Financial Advisory and Promotional Services
Published on 03/17/2026 at 21:30, 2 hours 6 minutes ago

Rainy Mountain Announces Appointment of Colton Griffith to Board of Directors
Published on 03/17/2026 at 21:10, 2 hours 26 minutes ago

BTU Announces Financing
Published on 03/17/2026 at 13:30, 10 hours 6 minutes ago

Hillcrest Energy Technologies Confirms ZVS PCS1000 Prototype on Track for June 2026

View all ACCESSWIRE

EQS Group

Published on 03/17/2026 at 21:21, 2 hours 14 minutes ago

KION GROUP AG successfully places a bond of € 500 million
Published on 03/17/2026 at 20:55, 2 hours 40 minutes ago

EQS-Adhoc: thyssenkrupp nucera lowers its sales and EBIT outlook for the Group and the gH2 segment for FY 2025/26 due to higher project costs
Published on 03/17/2026 at 18:07, 5 hours 28 minutes ago

POS-Transaction in Own Shares
Published on 03/17/2026 at 17:58, 5 hours 38 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/17/2026 at 17:45, 5 hours 50 minutes ago

FIGEAC AÉRO: THREE NEW WINS IN MEXICO

Les Echos

Published on 03/17/2026 at 07:00, 16 hours 36 minutes ago

Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 1 day 5 hours ago

Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 1 day 5 hours ago

Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 1 day 5 hours ago

Reporting on share buyback transactions carried out between March 9 and March 13, 2026
Published on 03/16/2026 at 17:45, 1 day 5 hours ago

Weekly share buyback

View all LES ECHOS COMFI WIRE